Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Package Insert for Estrogens to Be Revised
November 11, 2002
-
ARCHIVE Sankyo to Comarket Sysmex's Influenza Test Reagent
November 11, 2002
-
COLUMN Maurer's Healthcare Insight (35)
November 11, 2002
-
ARCHIVE Chuikyo Listens to Hospital Directors on DPC System
November 11, 2002
-
ARCHIVE Korosho to Gear Up Drafting of Medical Devices Industry Vision
November 11, 2002
-
ARCHIVE MEET THE LEADERS (10)
November 11, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF
November 11, 2002
-
ARCHIVE CDFS's Panel on Medical Devices to Prepare for New PAL Enforcement
November 11, 2002
-
ARCHIVE Ajinomoto Takes Over Shimizu Pharm
November 11, 2002
-
ARCHIVE JPA to Conduct Studies on Medical Benefits of Bungyo
November 11, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 11, 2002
-
ARCHIVE Tanabe Shifts to Independent Global Marketing
November 11, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 11, 2002
-
ARCHIVE Korosho to Standardize Definition, Duties of SMOs
November 11, 2002
-
ARCHIVE PI Forum Member Companies Maintain Interest in Drug Business
November 11, 2002
-
ARCHIVE TV Programs Should Be More Careful in Handling Healthcare Issues: Yamanouchi, Pfizer Seminar
November 11, 2002
-
ARCHIVE Roche Diagnostics: Accu-chek Compact Blood Glucose Meter
November 11, 2002
-
ARCHIVE FPMAJ Compiles Measures to Prevent Medical Accidents
November 11, 2002
-
ARCHIVE Life Science Summit Calls For Promotion of World's Leading R&D
November 11, 2002
-
ARCHIVE WORLD NEW IN BRIEF
November 11, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…